Articles tagged with Prostate Cancer
A significant proportion of men with advanced prostate cancer have inherited mutations in DNA repair genes, making them eligible for precision treatments such as PARP inhibitors. Genetic testing could help identify these patients and offer targeted therapies to improve their treatment outcomes.
Researchers at Ontario Institute for Cancer Research created protein signatures to accurately diagnose prostate cancer and distinguish between aggressive and non-aggressive disease. The findings could lead to a non-invasive 'liquid biopsy' that provides faster, cheaper, and easier detection of prostate cancer.
Researchers have discovered biomarkers using non-invasive liquid biopsies to identify aggressive disease in prostate cancer patients before surgery. The study uses urine samples from 210 patients and identifies a range of proteins that can help predict which patients have slow-growing versus aggressive cancer.
A team of researchers at KIT developed a 3D model for prostate cancer research using cryogels, which can replicate natural processes and examine tumor development. The model has been recognized as the top story on Prostate Cell News.
A new study reveals that a single gene can drive prostate differentiation in seminal vesicle epithelial cells, suggesting potential insights into prostate cancer development. The research found that inducing expression of the Nkx3.1 gene caused seminal vesicle cells to convert into a prostate-like state.
A new radiotherapy regime for prostate cancer has been shown to be as effective as the current standard treatment, but with fewer hospital visits and less side effects. The 20-dose course is expected to save the NHS tens of millions of pounds per year.
A new study by the Society of Nuclear Medicine and Molecular Imaging shows that PET/CT imaging using prostate-specific membrane antigen leads to highly accurate tumor detection and delineation, with a 67% accuracy rate.
Researchers found that men with prostate cancer who consumed tree nuts five or more times a week had a 34% lower risk of overall mortality. The study suggests that tree nuts may offer cardioprotective and anticarcinogenic benefits, supporting their inclusion in a healthy diet.
A study of US men found that mid-life PSA levels can accurately predict future risk of lethal prostate cancer. Screening PSA levels in men at mid-life may help identify those who are at greater risk and should be monitored more closely.
Research from Baylor College of Medicine found that Notch activation promotes metastasis in prostate cancer by upregulating FoxC2, a molecule important for metastatic potential. The study used a mouse model with prostate-specific loss-of-function Pten to demonstrate the role of Notch in prostate cancer progression.
Researchers at UCLA have found laser heat ablation to be a safe and effective treatment option for men with intermediate risk prostate cancer, with no serious adverse effects reported. The technique uses MRI guidance to target and destroy cancerous tissue, offering a middle ground between radical surgery and active surveillance.
The research article discusses experimental and clinical data on the pharmacological inhibition of the Akt/mTOR pathways, which play a vital role in prostate cancer. The blockade of this pathway may be necessary to increase standard therapies and improve treatment outcomes.
A recent study found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer. The imaging modality also correlates clearly with clinical outcomes and patient survival over time.
A large European study found that higher body mass index (BMI) and waist circumference are associated with an increased risk of high-grade prostate cancer. Men with greater adiposity have a higher risk of aggressive forms of the disease, highlighting the importance of maintaining a healthy weight.
A new Phase III clinical trial will evaluate if magnetic resonance imaging (MRI) can replace the current standard of care for diagnosing prostate cancer. The PRECISE trial aims to determine whether MRI imaging can spare some men from undergoing biopsies, reducing potential side effects.
A University of California San Diego study describes a new imaging biomarker that enhances MRI to differentiate aggressive prostate cancer from low-grade or benign tumors. The technology, called restriction spectrum imaging (RSI), allows for non-invasive detection and prediction of tumor grade without biopsy.
Researchers identified key metabolic pathways altered in prostate cancer, with a potential therapeutic target for castration-resistant prostate cancer. Studying tumor metabolism offers new possibilities for treatment.
A Loyola Medicine study found that robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays in obese prostate cancer patients. Compared to open surgery, robotic-assisted surgery was associated with a 83% lower rate of blood transfusions and a 72% lower rate of prolonged hospital stays.
Researchers developed a new approach to prostate cancer treatment using vessel-sparing radiation combined with MRI. The technique reduces side effects such as erectile dysfunction and bladder or rectal irritation while achieving high cure rates.
The IsoPSA test detects prostate cancer by identifying molecular changes in the prostate specific antigen (PSA) protein. It also differentiates between high-risk and low-risk disease, as well as benign conditions.
A longitudinal Nordic study shows that combining hormone therapy with local radiotherapy halves the risk of death from prostate cancer 15 years after diagnosis. Researchers found that treatments with radiotherapy reduced mortality rates from 34 to 17 percent.
A large analysis of medical records in Sweden found that men taking testosterone therapy for over a year had no increased risk of prostate cancer and, in fact, had their risk reduced by 50 percent. The study's findings suggest that balancing testosterone levels within a normal range may be key to protecting against aggressive disease.
Researchers from NewYork-Presbyterian and Weill Cornell Medicine found that the landmark national study's methodology was flawed, leading to misinterpreted results that questioned the effectiveness of PSA testing. They suggest reconsidering prostate cancer screening guidelines.
Effective patient-physician communication is crucial for prostate cancer survivors' physical and emotional well-being. A study of 1772 patients found that good communication at least 3 years after surgery is associated with improved quality of life.
Researchers have found that Hsp90 inhibitors specifically target and inactivate a mechanism used by prostate cancer cells to evade standard treatment. The findings suggest that these drugs could be effective in treating prostate cancers that have become resistant to treatment and started spreading.
A new model of care for patients with low-risk prostate cancer has been tested, improving patient outcomes by increasing surveillance rates among very low-risk patients. The evidence-based approach uses best practices to select and follow patients, enhancing acceptance and use of active surveillance disease management.
Groundbreaking research in 13 radiology subspecialities presented during the ARRS 2016 Annual Meeting. Notable findings include improved prostate cancer detection and grading using restriction spectrum imaging, reduced unnecessary biopsies via novel mammographic algorithm, and faster knee MRI acquisition with accelerated SPACE.
New technology allows for detailed analysis of prostate shape changes after treatment, potentially providing prognostic information and early biomarkers. The study, published in PLOS ONE, involves eight patients and plans to expand to 40 more, tracking long-term outcomes.
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) offers a higher cure rate than traditional approaches, with a 98.6% cure rate for prostate cancer patients. The treatment involves high-dose radiation beams delivered in just five treatments, resulting in fewer side effects and quicker recovery times.
A new cancer treatment approach uses microparticles and mesenchymal stem cells to deliver chemotherapy directly to tumor cells, reducing systemic toxicity. The method successfully kills tumor cells via a strong bystander effect, offering hope for targeted treatment of prostate cancer and potentially other diseases.
Researchers at the University of Missouri have discovered a compound that not only lowers cholesterol but also kills prostate cancer cells. The study found that the compound, initially developed as a cholesterol-fighting molecule, reduced prostate cancer cell growth and caused cancer cell death in human and mouse models.
A study published in the Journal of Urology found that up to 30% of men on active surveillance for low-risk prostate cancer may have metastases. Risk factors include Gleason score 7 and presence of Gleason pattern 4 on diagnostic biopsy.
Researchers found that common treatments for prostate cancer can suppress the immune system, preventing immunotherapies from working effectively. The study suggests careful regulation of treatment timing and dosage to maximize anti-tumor effects and prevent relapse.
A clinical trial confirms that a shortened radiotherapy schedule is as effective as conventional radiotherapy in treating low-risk prostate cancer patients. Patients treated with the shorter regimen experienced more mild side effects, but no difference in severe late side effects.
A national study found that a shorter, intensive radiation therapy schedule of about 5.5 weeks was comparable to the standard 8-week regimen in terms of controlling cancer, while also reducing treatment duration and costs. The researchers reported slightly more mild side effects in patients receiving the shorter schedule.
A new genetic urine test has been developed to predict high-grade prostate cancer, identifying 92 percent of men with elevated PSA levels who had high-grade cancers. The test could spare hundreds of thousands of men from unnecessary biopsies and reduce the risks associated with the procedure.
Researchers have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor levels in castration-resistant prostate cancer, stopping tumor growth. This novel approach targets the root cause of the problem - the overexpression of the AR gene and its protein.
The study suggests that PSA screening should be extended and higher biopsy thresholds used to preserve benefits while controlling harm and costs, potentially making it a more cost-effective strategy.
Researchers have identified 11 molecules capable of binding to the PSMA biomarker, making them potential treatments for prostate cancer. These ligands are suitable for synthesizing and have good pharmacokinetic parameters, increasing their effectiveness in clinical trials.
Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models. The treatment, which involves packaging and administering a small molecule called IPA-3, significantly slows the progression of cancer and forces cancerous cells to undergo apoptosis.
A new study found that active surveillance for low-risk prostate cancer significantly improves urinary function, reduces incontinence, and enhances sexual satisfaction. Men on active surveillance reported a similar quality of life to those without cancer, highlighting its potential as an alternative to curative treatment.
Researchers have identified new prostate cancer markers in urine that show high specificity and sensitivity. A combination of these biomarkers could lead to a more accurate and reliable test for early diagnosis.
Researchers have found a correlation between hypogonadism and high Gleason scores in prostate cancer patients. This association could help predict patient outcomes before surgery, allowing for more targeted treatment strategies.
Researchers at the University of Missouri found that surgery can greatly increase a man's chance of survival when traditional radiation therapy has failed. A complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.
A CWRU researcher is using plant viruses to detect and treat aggressive prostate and breast cancers. The lab will customize tobacco mosaic virus to target biomarkers of prostate cancer and deliver chemotherapy deep into breast tumor tissue.
Research at Duke University Medical Center found that prostate cancer patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. The study analyzed outcomes of 8,736 men with metastatic prostate cancer and provides valuable information on prognosis and treatment approaches.
Researchers at Karolinska Institutet and University of Oulu identified mechanisms explaining genetic variants' influence on prostate cancer risk. The study reveals widespread deregulation of androgen receptor function, a key player in prostate cancer.
Researchers have found a possible association between radiotherapy for prostate cancer and an increased risk of developing secondary cancers of the bladder, colorectal tract, and rectum. However, the absolute rates of these secondary cancers remain low compared to other treatment complications.
A new study by Northwestern University research found that low levels of vitamin D are associated with aggressive prostate cancer in men. Men with dark skin or limited sun exposure should get their vitamin D levels checked and supplement if necessary to reduce the risk of aggressive prostate cancer.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
A new study from The Ottawa Hospital and the University of Ottawa shows that men with slow-growing prostate tumors are increasingly adopting active surveillance, a monitoring approach that avoids unnecessary treatment. After five years of follow-up, about 59% of patients under active surveillance were still managed that way.
A new clinical trial has begun at Oxford and Sheffield to test a potential vaccine for prostate cancer. The vaccine aims to stimulate the immune system's attack on cancer cells by recognizing a specific protein found on their surface. If successful, future studies will assess its effectiveness in preventing disease progression.
Researchers at UT Southwestern Medical Center found that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy. This technology aims to improve surgical decision-making and reduce the amount of healthy tissue removed during prostate cancer surgery.
Florida State University researchers are working on a new approach to deciphering genetic data that may lead to more targeted prostate cancer treatments. They identified altered signal pathways in prostate cancer, which could help pinpoint genetic changes that matter in cancer development and progression.
A new device can detect prostate cancer in urine samples using a gas chromatography sensor system, allowing for earlier diagnosis and potentially reducing the need for invasive procedures. The technology has shown promising results in a pilot study involving 155 men.
A study published in Circulation found that prostate cancer survivors are at higher risk of developing cardiovascular disease due to hormone therapy. The Vanderbilt Cardio-oncology program is working to modulate these risks through collaborative care and personalized interventions.
Declines in PSA testing varied by physician type, with primary care physicians showing a larger decrease than urologists. The study suggests that perceptions of PSA screening benefits and conflicting guidelines may contribute to the differences.
A new review suggests that targeted antibiotic therapy before prostate biopsy may lower sepsis rates. The study found 27 men need to receive antibiotics to prevent one infection, paving the way for safer procedures.
A new class of drug, YELIVA™ (ABC294640), has shown promise in slowing the growth of castration-resistant prostate cancer cells by inhibiting the sphingolipid pathway. The study found that treatment with YELIVA™ increased dihydroceramide levels and reduced expression of key oncogenes.
Researchers discovered a new biomarker, pro-NPY, which correlates with increased risk of prostate cancer death. The study suggests that high pro-NPY levels can predict prostate cancer-related death among diagnosed patients who haven't received surgical treatment.